New hope for Tough-to-Treat blood cancer: experimental combo enters human testing
NCT ID NCT07283094
Summary
This early-stage study is testing the safety and initial effectiveness of adding a new drug, FHD-286, to a standard two-drug treatment for acute myeloid leukemia (AML). It is for adults with newly diagnosed high-risk AML or AML that has come back after one prior treatment. The main goal is to find a safe dose and see if the three-drug combination can better control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Montefiore Medical Center
RECRUITINGThe Bronx, New York, 10467, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.